Is NGEN or EVMN more profitable?

Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A N/A N/A Evommune N/A N/A N/A

Does the media favor NGEN or EVMN?

In the previous week, Evommune had 8 more articles in the media than NervGen Pharma. MarketBeat recorded 10 mentions for Evommune and 2 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of -0.02 beat Evommune's score of -0.41 indicating that NervGen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Evommune 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, MNPR or NGEN?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than NervGen Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A NervGen Pharma N/A N/A N/A -$0.09 N/A

Is MNPR or NGEN more profitable?

NervGen Pharma's return on equity of 0.00% beat Monopar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -12.84% -12.57% NervGen Pharma N/A N/A N/A

Does the media prefer MNPR or NGEN?

In the previous week, Monopar Therapeutics had 6 more articles in the media than NervGen Pharma. MarketBeat recorded 8 mentions for Monopar Therapeutics and 2 mentions for NervGen Pharma. Monopar Therapeutics' average media sentiment score of 0.39 beat NervGen Pharma's score of -0.02 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, NGEN or TECX?

NervGen Pharma is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A N/A -$0.09 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A

Is NGEN or TECX more profitable?

NervGen Pharma's return on equity of 0.00% beat Tectonic Therapeutic's return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A N/A N/A Tectonic Therapeutic N/A -32.33% -30.92%

Does the media favor NGEN or TECX?

In the previous week, Tectonic Therapeutic had 1 more articles in the media than NervGen Pharma. MarketBeat recorded 3 mentions for Tectonic Therapeutic and 2 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of -0.02 beat Tectonic Therapeutic's score of -0.25 indicating that NervGen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RGNX or NGEN?

In the previous week, REGENXBIO had 4 more articles in the media than NervGen Pharma. MarketBeat recorded 6 mentions for REGENXBIO and 2 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of -0.02 beat REGENXBIO's score of -0.07 indicating that NervGen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

NervGen Pharma (NGEN) Competitors

$2.12 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.11 -0.01 (-0.52%)

As of 07/2/2026 07:27 PM Eastern

Compare

NGEN vs. EVMN, MNPR, CTMX, TECX, and RGNX

Should you buy NervGen Pharma stock or one of its competitors? MarketBeat compares NervGen Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NervGen Pharma include Evommune (EVMN), Monopar Therapeutics (MNPR), CytomX Therapeutics (CTMX), Tectonic Therapeutic (TECX), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry.

How does NervGen Pharma compare to Evommune?

NervGen Pharma (NASDAQ:NGEN) and Evommune (NYSE:EVMN) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

In the previous week, Evommune had 8 more articles in the media than NervGen Pharma. MarketBeat recorded 10 mentions for Evommune and 2 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of -0.02 beat Evommune's score of -0.41 indicating that NervGen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evommune	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

NervGen Pharma presently has a consensus price target of $18.00, indicating a potential upside of 749.06%. Evommune has a consensus price target of $45.63, indicating a potential upside of 253.90%. Given NervGen Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe NervGen Pharma is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

NervGen Pharma has higher earnings, but lower revenue than Evommune. NervGen Pharma is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A
Evommune	$10M	46.43	-$68.87M	-$9.50	N/A

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
Evommune	N/A	N/A	N/A

Summary

NervGen Pharma and Evommune tied by winning 4 of the 8 factors compared between the two stocks.

How does NervGen Pharma compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

NervGen Pharma's return on equity of 0.00% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
NervGen Pharma	N/A	N/A	N/A

1.8% of Monopar Therapeutics shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 5.8% of NervGen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Monopar Therapeutics is trading at a lower price-to-earnings ratio than NervGen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A

In the previous week, Monopar Therapeutics had 6 more articles in the media than NervGen Pharma. MarketBeat recorded 8 mentions for Monopar Therapeutics and 2 mentions for NervGen Pharma. Monopar Therapeutics' average media sentiment score of 0.39 beat NervGen Pharma's score of -0.02 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monopar Therapeutics presently has a consensus target price of $108.75, indicating a potential upside of 11.21%. NervGen Pharma has a consensus target price of $18.00, indicating a potential upside of 749.06%. Given NervGen Pharma's higher probable upside, analysts plainly believe NervGen Pharma is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80

Summary

Monopar Therapeutics beats NervGen Pharma on 6 of the 11 factors compared between the two stocks.

How does NervGen Pharma compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

NervGen Pharma has lower revenue, but higher earnings than CytomX Therapeutics. NervGen Pharma is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$35.54M	18.29	-$17.37M	-$0.41	N/A
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A

In the previous week, NervGen Pharma had 2 more articles in the media than CytomX Therapeutics. MarketBeat recorded 2 mentions for NervGen Pharma and 0 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.00 beat NervGen Pharma's score of -0.02 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CytomX Therapeutics	Neutral
NervGen Pharma	Neutral

NervGen Pharma has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. NervGen Pharma's return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
NervGen Pharma	N/A	N/A	N/A

67.8% of CytomX Therapeutics shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 5.8% of NervGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CytomX Therapeutics currently has a consensus target price of $12.10, suggesting a potential upside of 216.75%. NervGen Pharma has a consensus target price of $18.00, suggesting a potential upside of 749.06%. Given NervGen Pharma's higher probable upside, analysts clearly believe NervGen Pharma is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80

Summary

NervGen Pharma beats CytomX Therapeutics on 8 of the 14 factors compared between the two stocks.

How does NervGen Pharma compare to Tectonic Therapeutic?

NervGen Pharma (NASDAQ:NGEN) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

62.6% of Tectonic Therapeutic shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NervGen Pharma is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

NervGen Pharma's return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
Tectonic Therapeutic	N/A	-32.33%	-30.92%

NervGen Pharma presently has a consensus target price of $18.00, indicating a potential upside of 749.06%. Tectonic Therapeutic has a consensus target price of $79.40, indicating a potential upside of 109.33%. Given NervGen Pharma's higher possible upside, research analysts clearly believe NervGen Pharma is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Tectonic Therapeutic had 1 more articles in the media than NervGen Pharma. MarketBeat recorded 3 mentions for Tectonic Therapeutic and 2 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of -0.02 beat Tectonic Therapeutic's score of -0.25 indicating that NervGen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tectonic Therapeutic beats NervGen Pharma on 6 of the 11 factors compared between the two stocks.

How does NervGen Pharma compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, REGENXBIO had 4 more articles in the media than NervGen Pharma. MarketBeat recorded 6 mentions for REGENXBIO and 2 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of -0.02 beat REGENXBIO's score of -0.07 indicating that NervGen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.1% of REGENXBIO shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 5.8% of NervGen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NervGen Pharma has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. NervGen Pharma's return on equity of 0.00% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
NervGen Pharma	N/A	N/A	N/A

REGENXBIO presently has a consensus target price of $23.82, indicating a potential upside of 79.35%. NervGen Pharma has a consensus target price of $18.00, indicating a potential upside of 749.06%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NervGen Pharma is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80

NervGen Pharma has lower revenue, but higher earnings than REGENXBIO. NervGen Pharma is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$87.82M	7.82	-$193.88M	-$5.60	N/A
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A

Summary

NervGen Pharma beats REGENXBIO on 8 of the 14 factors compared between the two stocks.

Get NervGen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGEN vs. The Competition

Export

Metric	NervGen Pharma	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$170.94M	$3.14B	$5.20B	$12.48B
Dividend Yield	N/A	15.27%	16.11%	6.52%
P/E Ratio	-23.56	13.51	23.91	24.70
Price / Sales	N/A	2,827.48	216.83	99.49
Price / Cash	N/A	25.31	35.06	57.09
Price / Book	N/A	5.15	13.25	6.46
Net Income	N/A	-$34.63M	$113.80M	$337.01M
7 Day Performance	13.37%	1.00%	0.93%	1.69%
1 Month Performance	13.98%	0.85%	1.08%	3.81%
1 Year Performance	N/A	12.21%	10.03%	23.90%

NervGen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGEN NervGen Pharma	2.9105 of 5 stars	$2.12 flat	$18.00 +749.1%	N/A	$170.94M	N/A	N/A	N/A	News Coverage
EVMN Evommune	2.3149 of 5 stars	$16.85 -33.1%	$49.25 +192.2%	N/A	$616.09M	$10M	N/A	45	Analyst Forecast High Trading Volume
MNPR Monopar Therapeutics	1.4517 of 5 stars	$90.10 +2.8%	$107.67 +19.5%	+172.6%	$598.34M	N/A	N/A	10	News Coverage Analyst Forecast Gap Down
CTMX CytomX Therapeutics	1.9749 of 5 stars	$3.48 +2.2%	$12.10 +248.1%	+53.4%	$596.51M	$35.54M	N/A	170	Positive News
TECX Tectonic Therapeutic	2.8745 of 5 stars	$31.67 -1.0%	$79.40 +150.7%	+74.4%	$595.44M	N/A	N/A	120	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGEN) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NervGen Pharma (NGEN) Competitors

NGEN vs. EVMN, MNPR, CTMX, TECX, and RGNX

How does NervGen Pharma compare to Evommune?

Summary

How does NervGen Pharma compare to Monopar Therapeutics?

Summary

How does NervGen Pharma compare to CytomX Therapeutics?

Summary

How does NervGen Pharma compare to Tectonic Therapeutic?

Summary

How does NervGen Pharma compare to REGENXBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NervGen Pharma (NGEN) Competitors

NGEN vs. EVMN, MNPR, CTMX, TECX, and RGNX

How does NervGen Pharma compare to Evommune?

Does the media favor NGEN or EVMN?

Do analysts recommend NGEN or EVMN?

Which has preferable valuation & earnings, NGEN or EVMN?

Is NGEN or EVMN more profitable?

Summary

How does NervGen Pharma compare to Monopar Therapeutics?

Is MNPR or NGEN more profitable?

Do institutionals and insiders believe in MNPR or NGEN?

Which has better valuation and earnings, MNPR or NGEN?

Does the media prefer MNPR or NGEN?

Do analysts recommend MNPR or NGEN?

Summary

How does NervGen Pharma compare to CytomX Therapeutics?

Which has better earnings and valuation, CTMX or NGEN?

Does the media prefer CTMX or NGEN?

Is CTMX or NGEN more profitable?

Do insiders & institutionals have more ownership in CTMX or NGEN?

Do analysts recommend CTMX or NGEN?

Summary

How does NervGen Pharma compare to Tectonic Therapeutic?

Do institutionals & insiders believe in NGEN or TECX?

Which has better earnings & valuation, NGEN or TECX?

Is NGEN or TECX more profitable?

Do analysts prefer NGEN or TECX?

Does the media favor NGEN or TECX?

Summary

How does NervGen Pharma compare to REGENXBIO?

Does the media refer more to RGNX or NGEN?

Do institutionals and insiders believe in RGNX or NGEN?

Is RGNX or NGEN more profitable?

Do analysts prefer RGNX or NGEN?

Which has better earnings and valuation, RGNX or NGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools